THOUSAND OAKS, Calif - May 22, 2002 -- Amgen Inc. (Nasdaq:AMGN) announced
today that it has filed a Registration Statement on Form S-3 with the Securities
and Exchange Commission. The registration statement relates to the resale by the
holders of Amgen´s Liquid Yield Option Notes due 2032 (the "LYONs") and shares
of Amgen common stock issuable upon conversion and/or redemption of the LYONs.
Amgen´s issuance of the LYONs, which raised approximately $2.8 billion in gross
proceeds, was completed on March 1, 2002.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission, but has not yet become effective.
These securities may not be sold, nor may offers to buy be accepted, prior to
the time the registration statement becomes effective. This press release shall
not constitute either an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission reports filed by Amgen,
including our most recent Form 10-Q. Amgen conducts research in the biotechnology/pharmaceutical
field where movement from concept to product is uncertain; consequently, there
can be no guarantee that any particular product candidate will be successful
and become a commercial product.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and foreign government
regulatory authorities. In addition, sales of our products are affected by reimbursement
policies imposed by third party payors, including governments, private insurance
plans and managed care providers. These government regulations and reimbursement
policies may affect the development, usage and pricing of our products.
In addition, while we routinely obtain patents for our products
and technology, the protection offered by our patents and patent applications
may be challenged, invalidated or circumvented by our competitors.
Because forward-looking statements involve risks and uncertainties,
actual results may differ materially from current results expected by Amgen.
Amgen is providing this information as of May 22, 2002 and expressly disclaims
any duty to update information contained in this press release.
Amgen is a global biotechnology company that discovers,
develops, manufactures and markets important human therapeutics based on advances
in cellular and molecular biology.
# # #
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)